Thomas Sears

6PUBLICATIONS
32CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersMultiphysics flows (incl. multiphase and reacting flows)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 12, 2026
STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways.

Mark W Youngblood, Shashwat Tripathi, Hinda Najem

|Dec 16, 2025
Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel.

Mark W Youngblood, Abha Kumari, Yoon-Tae Kang

|Mar 13, 2025
<i>F3</i> Expression Drives Sensitivity to the Antibody-Drug Conjugate Tisotumab Vedotin in Glioblastoma.

Thomas K Sears, Wenxia Wang, Michael Drumm

|Nov 26, 2022
Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts.

Matthew McCord, Elizabeth Bartom, Kirsten Burdett

|Apr 25, 2022
R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.

Thomas K Sears, Kevin D Woolard

|Aug 23, 2021
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.

Thomas K Sears, Craig M Horbinski, Kevin D Woolard

Pageof 1

Frequent Collaborators

3 joint publications

Craig M Horbinski

3 joint publications

Kathleen McCortney

2 joint publications

Matthew McCord

2 joint publications

Mark W Youngblood